Long COVID Labs (LCL) employs a multifaceted value capture model that combines near-term revenue generation with long-term innovation in therapeutics. By repurposing FDA-approved drugs like Paxlovid and leveraging existing antibody technologies, LCL aims to fast-track clinical trials and monetize treatments rapidly. This approach minimizes the time and cost traditionally associated with drug development, allowing the organization to generate early revenue streams if these treatments prove effective. Simultaneously, LCL invests in groundbreaking research, such as Long-Acting Antibody (LAAb) therapies, which could become part of the standard COVID care protocol, potentially capturing a share of the $25 billion vaccine market.

By operating as a therapeutics platform, LCL further unlocks value through its decentralized research funding model, enabling it to crowdsource innovative treatment ideas and support agile, community-driven clinical trials. This dynamic ecosystem not only accelerates discovery but also ensures that the DAO structure aligns the incentives of scientists, patients, and investors. With its dual focus on immediate impact and scalable, transformative care solutions, LCL creates a self-sustaining cycle of innovation and profitability while addressing one of the most urgent health crises of our time.